Harvard Bioscience (HBIO) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.61 -0.69%
EPS Growth %: -800.0%
Financial Fact:
Other, net: -64K
Today's EPS Names:
COHR, ATS, SICP, More
EPS Growth %: -800.0%
Financial Fact:
Other, net: -64K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $27.15 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- HCI Group (HCI) Tops Q3 EPS by 245c
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
